News

FDA needs more sophisticated approach to drug safety

BMJ 2005; 330 doi: 10.1136/bmj.330.7501.1166-b (Published 19 May 2005)
Cite this as: BMJ 2005;330:1166.3

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Bryan Christie
  1. Edinburgh

    A much more sophisticated approach is needed on drug safety if the recent debacle concerning rofecoxib (Vioxx) is not to be repeated. This is the view of one of the doctors who first raised fears about the cyclo-oxygenase-2 (COX 2) inhibitor.

    Dr Garret FitzGerald, director of the Institute for Translational Medicine and Therapeutics at the University of Pennsylvania, told a conference in Edinburgh that the problems surrounding rofecoxib could well happen again in a different guise. He blamed the problem on …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    Read related article

    See previous polls

    BMJ most popular